Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 36, 2006 - Issue 5
263
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Species differences in the pharmacokinetics and metabolism of reparixin in rat and dog

, , , , , , , , , & show all
Pages 419-440 | Received 09 Dec 2005, Published online: 22 Sep 2008
 

Abstract

The pharmacokinetics and metabolism of reparixin (formerly repertaxin), a potent and specific inhibitor of the chemokine CXCL8, were investigated in rats and dogs after intravenous administration of [14C]-reparixin L-lysine salt. Protein binding of reparixin was investigated in vitro in rat, dog, rabbit, cynomolgus monkey and human plasma. Plasma protein binding of reparixin was >99% in the laboratory animals and humans up to 50 µg ml−1, but lower at higher concentrations. Although radioactivity was rapidly distributed into rat tissues, Vss was low (about 0.15 l kg−1) in both rat and dog. Nevertheless, reparixin was more rapidly eliminated in rats (t½ ∼ 0.5 h) than in dogs (t½ ∼ 10 h). Systemic exposure in dog was due primarily to parent drug, but metabolites played a more prominent role in rat. Oxidation of the isobutyl side-chain was the major metabolic pathway in rat, whereas hydrolysis of the amide bond predominated in dog. Urinary excretion, which accounted for 80–82% of the radioactive dose, was the major route of elimination in both species, and biotransformation of reparixin was complete before excretion.

Acknowledgements

The authors gratefully acknowledge the technical assistance of Dr S. Johnson for performing the TLC work, Ms T. Houchen and Mr R. A. Shabir for QWBA, and Mr I. Ward, Mr A. Roth and Mr A. Miller for assistance with the bioanalysis. Part of this work was presented in poster form at the European ISSX Meeting, Nice, France, in June 2005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.